Skip to main content

Israeli COVID-19 vaccine pill to begin human trials

Israel is home to a few experimental treatments for the coronavirus.

An Israeli pharmaceutical company will soon begin testing its COVID-19 vaccine pill on humans.

Oramed Pharmaceuticals Inc. announced today that its subsidiary Oravax received permission from South African authorities to begin the first phase of the oral vaccine’s trial. Oramed can begin enrolling patients for the trial and is currently preparing to actually begin administering the pill, according to the Jerusalem-based firm’s statement.

Israel, a world leader in technology, is not new to experimental strategies for fighting the pandemic. A protein-utilizing drug developed in Tel Aviv showed promising results fighting the coronavirus earlier this year. A nasal spray that apparently kills the virus is also being produced in the country. Israel was additionally one of the first countries in the world to begin administering vaccine booster shots.

Vaccines against COVID-19 are presently administered via shots to the arm. A pill could make distributing vaccines much simpler, since pills do not expire as quickly and can be produced en masse.

Join hundreds of Middle East professionals with Al-Monitor PRO.

Business and policy professionals use PRO to monitor the regional economy and improve their reports, memos and presentations. Try it for free and cancel anytime.


The Middle East's Best Newsletters

Join over 50,000 readers who access our journalists dedicated newsletters, covering the top political, security, business and tech issues across the region each week.
Delivered straight to your inbox.


What's included:
Our Expertise

Free newsletters available:

  • The Takeaway & Week in Review
  • Middle East Minute (AM)
  • Daily Briefing (PM)
  • Business & Tech Briefing
  • Security Briefing
  • Gulf Briefing
  • Israel Briefing
  • Palestine Briefing
  • Turkey Briefing
  • Iraq Briefing

Premium Membership

Join the Middle East's most notable experts for premium memos, trend reports, live video Q&A, and intimate in-person events, each detailing exclusive insights on business and geopolitical trends shaping the region.

$25.00 / month
billed annually

Become Member Start with 1-week free trial

We also offer team plans. Please send an email to and we'll onboard your team.

What's included:
Our Expertise AI-driven

Memos - premium analytical writing: actionable insights on markets and geopolitics.

Live Video Q&A - Hear from our top journalists and regional experts.

Special Events - Intimate in-person events with business & political VIPs.

Trend Reports - Deep dive analysis on market updates.

All premium Industry Newsletters - Monitor the Middle East's most important industries. Prioritize your target industries for weekly review:

  • Capital Markets & Private Equity
  • Venture Capital & Startups
  • Green Energy
  • Supply Chain
  • Sustainable Development
  • Leading Edge Technology
  • Oil & Gas
  • Real Estate & Construction
  • Banking

Start your PRO membership today.

Join the Middle East's top business and policy professionals to access exclusive PRO insights today.

Join Al-Monitor PRO Start with 1-week free trial